Nikkei Industry Sector
Pharmaceuticals
Overview
Japan's pharmaceutical sector includes both large domestic-focused drug makers and globally operating biopharmaceutical companies with significant international revenue. The industry combines deep scientific capability with strong regulatory relationships and a large aging domestic patient population that drives consistent baseline demand.
Current Trend
Japanese pharma companies are accelerating globalization through overseas acquisitions, licensing deals, and co-development partnerships—particularly in oncology and rare diseases. Biosimilar manufacturing, leveraging Japan's precision production expertise, is also emerging as a significant growth opportunity as biologic patents expire globally.
Companies in This Sector
9
Today's Avg. Price Change
+1.39%
Simple average of constituent stock price changes vs. previous close. Not a sector index.
Updated: 2026-10-30 (JST)
Position in Japan
Japan is the world's third-largest pharmaceutical market by value, providing a stable and substantial home base. The National Health Insurance system, while exerting downward pricing pressure through biennial drug price revisions, ensures broad market access for approved therapies and a predictable revenue floor.
Latest Press Releases
27
Oct
Otsuka Holdings Co.,Ltd. JP3188220002
2026-10-26 Otsuka Holdings Co.,Ltd. “Otsuka BioVentures, a US-based corporate venture capital firm, has officially launched, accelerating collaborations with promising startups through strategic equity investments.”
27
Oct
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-10-26 CHUGAI PHARMACEUTICAL CO.,LTD. “Roche's announcement regarding cefaxelcene sodium (detailed data from the interim analysis of the Phase III IMAgINATION trial).”
27
Oct
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-10-26 CHUGAI PHARMACEUTICAL CO.,LTD. “Roche's announcement regarding divarasib (presentation of the latest data on KRAS G12C mutation-positive non-small cell lung cancer in ESMO).”
24
Oct
Otsuka Holdings Co.,Ltd. JP3188220002
2026-10-23 Otsuka Holdings Co.,Ltd. “The final results of the Phase 3 trial of the IgA nephropathy treatment drug "VOYXACT® (sibeprenelimab)" were presented at the American Society of Nephrology (ASN) meeting – demonstrating stabilization of renal function and reduction of the risk of disease progression and renal failure, offering new hope to patients with IgA nephropathy.”
24
Oct
Astellas Pharma Inc. JP3942400007
2026-10-23 Astellas Pharma Inc. “The antibody-drug conjugate PADCEV™ (enfortumab vedotin) has received approval in Europe for an additional indication in combination with pembrolizumab for resectable muscle-invasive bladder cancer, regardless of whether cisplatin is indicated.”
23
Oct
Otsuka Holdings Co.,Ltd. JP3188220002
2026-10-22 Otsuka Holdings Co.,Ltd. “Taiho Pharmaceutical installs new solar power generation equipment at its drug discovery center in Tsukuba – promoting carbon neutrality initiatives.”
23
Oct
DAIICHI SANKYO COMPANY,LIMITED JP3475350009
2026-10-22 DAIICHI SANKYO COMPANY,LIMITED “The PDF file (293.9KB) regarding the approval of Enhertu® for multiple HER2-positive solid tumors in China will open in a new window.”
22
Oct
Shionogi & Co.,Ltd. JP3347200002
2026-10-21 Shionogi & Co.,Ltd. “Regarding the presentation of new research findings on the anti-COVID-19 drug encitrelvir fumarate at Infectious Diseases Association Week of America (IDWeek 2026).”
22
Oct
Shionogi & Co.,Ltd. JP3347200002
2026-10-21 Shionogi & Co.,Ltd. “Presentation of real-world evidence and analytical data demonstrating favorable clinical efficacy of cefiderocol at Infectious Diseases Association Week of America (IDWeek2026).”
22
Oct
Shionogi & Co.,Ltd. JP3347200002
2026-10-21 Shionogi & Co.,Ltd. “Regarding the announcement of the results of the global Phase 3 clinical trial (OASIS trial) of the novel antifungal drug ororofim at Infectious Diseases Week of America (IDWeek 2026).”
20
Oct
Otsuka Holdings Co.,Ltd. JP3188220002
2026-10-19 Otsuka Holdings Co.,Ltd. “Zipalertinib demonstrates clinically meaningful intratracranial antitumor activity in patients with NSCLC with EGFR exon 20 insertion or uncommon EGFR mutations and active CNS metastases (link to Taiho Oncology English page).”
17
Oct
Otsuka Holdings Co.,Ltd. JP3188220002
2026-10-16 Otsuka Holdings Co.,Ltd. “Paradise Ultrasonic Renal Denervation System wins TIME magazine's "Best Inventions of 2026" award (link to Recor English page).”
17
Oct
Otsuka Holdings Co.,Ltd. JP3188220002
2026-10-16 Otsuka Holdings Co.,Ltd. “Notice of price revision for some products – effective for deliveries from January 1st, 2027 (Friday).”
17
Oct
Otsuka Holdings Co.,Ltd. JP3188220002
2026-10-16 Otsuka Holdings Co.,Ltd. “Otsuka Warehouse establishes "Quality Culture Declaration" to promote advanced and stable supply of pharmaceutical logistics through the use of digital QMS.”
17
Oct
Eisai Co.,Ltd. JP3160400002
2026-10-16 Eisai Co.,Ltd. “At the European Society for Medical Oncology (ESMO) Annual Meeting 2026, we will present further evidence in the field of oncology—new insights into Lenvima® (lenvatinib)-based combination therapy from the Phase III LITESPARK-011 and LITESPARK-012 clinical trials for advanced renal cell carcinoma, new findings from translational studies of advanced or recurrent endometrial cancer obtained from exploratory biomarker analysis of the Phase III LEAP-001 trial, and new findings from "Patients Raise Their Voices."”
17
Oct
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-10-16 CHUGAI PHARMACEUTICAL CO.,LTD. “Roche's announcement regarding Enspring (US FDA approval for thyroid eye disease).”
17
Oct
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-10-16 CHUGAI PHARMACEUTICAL CO.,LTD. “Chugai Pharmaceutical receives the 2026 Porter Prize.”
17
Oct
Shionogi & Co.,Ltd. JP3347200002
2026-10-16 Shionogi & Co.,Ltd. “NEDO's "Prize-Based Program/Development of Social Problem Solutions Using Quantum Computing" awarded first place in the Quality of Life (QoL) category – recognized for its drug discovery research approach utilizing quantum computers and supercomputers.”
16
Oct
Otsuka Holdings Co.,Ltd. JP3188220002
2026-10-15 Otsuka Holdings Co.,Ltd. “Paradise Ultrasonic Renal Denervation System: Winner of the "2026 Good Design Award".”
14
Oct
Eisai Co.,Ltd. JP3160400002
2026-10-13 Eisai Co.,Ltd. “Let Snorlax's daily life inspire you to reconsider your sleep! An educational video highlighting the importance of sleep has been released in collaboration with 'Pokémon Sleep'.”